Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, shared her insights during a discussion with Allen Wilbanks regarding the promising potential of TT fields (Tumor Treating Fields) as a treatment modality for cancer patients.When asked about patient subgroups that might benefit more or less from TT field treatment, Dr. Leal responded with a wealth of knowledge and confidence. “I think, from the results of the Lunar trial,” she began, “what we saw was a striking improvement in overall survival in the ICI-treated subgroups.” She went on to elaborate, emphasizing the significance of combining immune checkpoint inhibitors (ICI)…
Author: admin
In this informative video, viewers will gain valuable insights into the groundbreaking research discussed by medical experts Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, and Allen Wilbanks. The discussion revolves around the implications of recent findings for clinical practice in the field of oncology.Dr. Ticiana Leal begins by highlighting the significance of the study, emphasizing its novelty in demonstrating an improvement in overall survival for patients who have previously undergone platinum-based chemotherapy and are now being treated with immune checkpoint inhibitors (ICIs) as a first-line therapy. She underscores the importance of these findings as a potential…
By: Allen Wilbanks Date: September 27, 2023 Stephen Oh, MD PhD, took the podium to present his research in a room filled with anticipation. He began with a casual tone, saying, “I just wanna level set for the audience here. I’m gonna try to keep this science-y. I can’t promise you I won’t say something stupid.” He humorously added, “And, since I have two talks, if you wanna do a gladiator-style thumbs up or thumbs down after the first one, as to whether I’m allowed to proceed, I’m okay with that.” REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS…
By: Allen Wilbanks Date: September 27,2023 In a recent presentation, Elizabeth Brem, MD shared her perspective on the utilization of minimal residual disease (MRD) technology in clinical trials and its potential to transform patient care. She emphasized the various applications of MRD, including its role in guiding time-limited therapies to reduce toxicity, intensifying or extending therapy based on patient needs, and altering therapy strategies, especially in conditions like CLL. Dr. Brem noted that solid tumor colleagues have been more advanced in utilizing MRD technology clinically, while the lymphoma community is catching up to leverage it for patient care improvements. REGISTER NOW…
In a groundbreaking lunar trial, Ticiana Leal, MD, a distinguished expert from the Winship Cancer Institute of Emory University, spearheaded a Phase three study that promised to reshape the landscape of cancer treatment. This global, randomized study aimed to scrutinize the safety and efficacy of tumor treating fields (TT fields) therapy in conjunction with standard-of-care therapies. The subjects of this trial were patients grappling with advanced non-small cell lung cancer, a cohort that had experienced progression after undergoing platinum-based chemotherapy.In a nutshell, the primary objective was to fathom the impact of TT fields therapy, either combined with an immune checkpoint…
Ticiana Leal, MD, is at the forefront of an intriguing and evolving discussion centered on the mechanism underlying tumor treating fields (TT fields). These fields are a topic of great interest in the field of oncology, and Dr. Leal’s expertise shines through as she delves into the question at hand: how do tumor-treating fields actually work?TT fields, a novel approach in cancer therapy, harness the power of electric fields to interact with electrically charged components within the human body, specifically targeting dividing cancer cells. Their precise mode of action revolves around disrupting the crucial process of mitosis, where cells divide…
By: Allen Wilbanks Date: September 27, 2023 Myeloproliferative neoplasms (MPNs) are a group of blood disorders characterized by the overproduction of blood cells in the bone marrow. Andrew Kuykendall, MD, a well-known hematopathologist and engaging speaker, recently addressed the topic of “WHO versus ICC and the Implications within MPNs” in a presentation. Despite not being directly involved in either classification system, Dr. Kuykendall offered a unique third-party perspective on the matter, comparing and contrasting the two systems and their implications for MPNs. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…
By: Allen Wilbanks Date: September 27 /2023 John Leonard, MD, a prominent figure in the field of oncology, delivered a thought-provoking presentation at a medical conference. His words were a reflection of his deep commitment to improving patient outcomes and quality of life. In his address, he discussed various aspects of treating lymphomas, particularly follicular lymphoma and diffuse large B cell lymphoma, emphasizing the importance of considering these factors when making treatment decisions. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…
By: Allen Wilbanks Date: 09/27/2023 William Shomali, MD, is a respected expert in systemic mastocytosis, known for his collaborative work with Jason Gottlieb at Stanford University. In a recent presentation, he shared valuable insights on this complex condition. Dr. Shomali began by expressing gratitude for the invitation and acknowledged MD Education for arranging the event. He then delved into systemic mastocytosis, emphasizing its challenging diagnosis due to the loss of granules in fixed tissue samples. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…
By: Allen Wilbanks Date: 09/27/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Sandeep Dave, MD, discussed the challenges of classifying and treating various blood cancers, including diffuse large cell lymphoma, follicular lymphoma, mantle cell lymphoma, and peripheral T cell lymphomas. He emphasized the importance of genomic profiling in understanding the heterogeneity of these diseases. For diffuse large cell lymphoma, Dr. Dave highlighted the complexity of subgrouping patients based on genetic alterations,…
By: Pankit Vachhani, MD Date: 09/22/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The audience was eagerly awaiting the insights of Dr. Pankit Vachhani, a long-time friend and mentee. As the presentation commenced on “Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes,” attendees were in for a comprehensive exploration of the topic. Despite his usual penchant for occupying the back seats, Dr. Vachhani humorously admitted, “Usually, I’m the guy who sits in…
By: Christopher Flowers, MD Date: 09/22/2023 Dr. Christopher Flowers of MD Anderson Cancer Center expressed his gratitude to Sandeep for his excellent talk, acknowledging it as a perfect precursor to his own discussion on integrating tools into clinical practice and trials. Dr. Flowers shared his relevant disclosures, mainly involving his role as a consultant in lymphoma therapy development and his work in the Division of Cancer Medicine. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US…
In a conversation hosted by Allen Wilbanks, Solange Peters, MD, PhD, a full professor and chair of medical oncology specializing in thoracic malignancies at the University Hospital of Lausanne in Switzerland, discussed the remarkable findings from the CheckMate 227 trial, particularly the six-year outcomes of Nivolumab and Ipilimumab as first-line treatment for metastatic non-small cell lung cancer.Dr. Peters emphasized that Nivolumab and Ipilimumab, being chemotherapy-free, offer an intriguing approach based solely on immune responses. Another key aspect is that the treatment stops at two years, allowing researchers to evaluate the long-term effects of promoting an immune response.Regarding the use of…
an AML-ALL US Focus Meeting 2023 video
Jack West, MD is an associate professor in medical oncology specializing in thoracic oncology at the City of Hope Comprehensive Cancer Center in the Los Angeles area. Recently, he discussed the highly anticipated FLAURA2 trial during the World Conference on Lung Cancer in Singapore. In his words, “Hi, I’m Jack West. I’d like to talk about the FLAURA2 trial, which was among the most anticipated presentations at the just completed World Conference on Lung Cancer in Singapore.”The FLAURA2 trial aimed to compare the efficacy of Osimertinib as a single agent versus Osimertinib combined with chemotherapy as a first-line treatment for…
In a discussion with Allen Wilbanks from Oncology Tube, Brandon McNaughton, CEO & Founder of Akadeum Life Sciences, shed light on the innovative Akadeum’s human T cell activation and expansion kit and its impact on cell therapy. McNaughton explained the advantages of their microbubble-based technology compared to traditional methods, highlighting its gentleness, scalability, and compatibility with various cell culture systems.He stated, “What’s different about what we do, which is using tiny floating particles, we call them micro bubbles to essentially reach into a sample, essentially a blood bag that was derived from a phoresis or Luca pack. We use microbubbles…
In the pivotal phase 3 LUNAR study, Ticiana Leal, MD, and her colleagues made a groundbreaking discovery that could revolutionize the treatment of metastatic non-small-cell lung cancer (NSCLC) in patients who have experienced disease progression following platinum-based therapy. The study, which aimed to evaluate the efficacy and safety of TTFields therapy in combination with standard systemic therapy, yielded remarkable results.Dr. Leal stated, “The randomized, pivotal phase 3 LUNAR study provides level 1 evidence that TTFields therapy, an innovative, locoregional treatment method, applied concomitantly with standard systemic therapy significantly improves overall survival in patients with metastatic non-small-cell lung cancer following progression…
OneOncology, a rapidly expanding national platform for independent medical practices, proudly announces the completion of 25 distinctive oncology and hematology pathways. These pathways are now integrated into the platform’s clinical decision support tool, a testament to OneOncology’s dedication to precision and excellence. Lisa Sowinski-Raff PharmD, serving as Vice President of Pharmacy Services, plays a pivotal role in this achievement.OneOncology adopts a physician-driven approach to pathway development, led by Medical Director Edward Arrowsmith, MD. Experts in gastrointestinal, genitourinary, breast, lung, and hematology, along with disease subject matter experts in gynecology and head and neck specialties, meticulously craft and continuously update these…
Timothy Looney, PhD – Senior Director, Immunology and Bioinformatics at Singular Genomics By: Timothy Looney, PhD Date: 9/12/2023 The topic at hand revolves around “Immune-Related Adverse Events (IRAEs)” in the context of cancer treatment using “Immune Checkpoint Inhibitors (ICIs).” Timothy Looney, a prominent researcher with a PhD, discusses the significance of IRAEs in cancer immunotherapy. IRAEs are adverse events that occur when therapeutic agents like ICIs activate T cells, causing them to mistakenly target healthy tissues, leading to damage or destruction. These events, which can range from mild to life-threatening, are a major concern in cancer immunotherapy due to the…
The interview with Jill O’Donnell-Tormey, PhD, delves into the vital topic of cancer immunotherapy and research, emphasizing the transformative potential of harnessing the human immune system to combat various forms of cancer. Throughout the conversation, O’Donnell-Tormey provides valuable insights and perspectives on key areas of focus within the field. Here are some direct quotes from her on these topics:On the mission of the Cancer Research Institute (CRI):”We are a non-profit organization that’s been around for 70 years with the singular view that your immune system could be harnessed as a way to treat, control, and potentially cure all cancers.”On the…
In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and priority review for TIBSOVO in the treatment of IDH1-mutated relapsed or refractory myelodysplastic syndromes (MDS). The acceptance marks a significant milestone in advancing targeted therapies for patients facing limited options in this challenging disease context.TIBSOVO’s clinical data submission showcased remarkable results, with complete remissions achieved in approximately 40% of patients and an overall response rate of 83.3% among those with relapsed or refractory IDH1-mutated MDS. These outcomes far exceed existing treatment options, underscoring TIBSOVO’s potential as a transformative therapy for…
Marwan Fakih, MD – City of Hope – FDA Approval of LONSURF in combination with Bevacizumab The FDA approval of Lonsurf plus Bevacizumab represents a significant breakthrough in the treatment of metastatic colorectal cancer. This combination therapy offers new hope for patients who have previously exhausted their treatment options, providing substantial improvements in both overall survival and progression-free survival. The clinical trial results from the Sunlight trial have solidified Lonsurf plus Bevacizumab as the standard third-line treatment for metastatic colorectal cancer, with potential implications for future research and control arms in clinical trials. Physicians are encouraged to consider this combination…
Joshua Brody, MD – Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount SinaiHess Center for Science and Medicine – Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming What is the role of primed CD8 T-cells in cancer immunotherapies, and how does their recognition of tumor antigens presented on MHC-I contribute to the antitumor response?What are the critical factors in loading dendritic cells (DC) with tumor antigens, and how can we optimize this process to enhance antitumor T-cell responses?Can you explain the advantages and limitations of using neoantigen vaccines based on individualized tumor exome and RNA…
In the interview with Allen Wilbanks of OncologyTube, Peter Langmuir, the Vice President of Oncology Drug Development at Incyte, discussed the Agave 201 trial and its outcomes. Mr. Langmuir explained, “The Agave 201 trial was a clinical trial in patients with chronic GVHD, looking at the drug axatilimab, a monoclonal antibody against the CSF1 receptor. That was originally developed by our partners at syntax. And this trial was initiated by them to do two things. First of all, one was to try to identify the most appropriate dose of axatilimab to use in these patients based on both safety and…
The recent approval by the Food and Drug Administration (FDA) of mirvetuximab soravtansine-gynx (Elahere) marks a significant advancement in the treatment landscape for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This article aims to provide oncologists with a comprehensive overview of the efficacy, safety profile, and prescribing considerations associated with this novel therapeutic agent. Efficacy Evaluation: Study 0416 Mirvetuximab soravtansine-gynx’s (Elahere) approval was based on data from Study 0416 (MIRASOL), a pivotal multicenter trial involving 453 patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients enrolled in the study had…
Mark Schoenberg, MD- UrologyGenitourinary (GU) CancerBladder Cancer-The Montefiore Medical Center and The Albert Einstein College of Medicine at UroGen Pharma What is UGN-102, and what is its potential role as the first non-surgical therapy for LG-IR-NMIBC? Could you explain the primary endpoints achieved in both the ATLAS and ENVISION clinical trials for UGN-102? In the ATLAS trial, UGN-102 showed a 55% reduction in the risk of recurrence, progression, or death compared to TURBT. How significant is this finding for patients with LG-IR-NMIBC? What was the complete response rate at three months observed in the ENVISION trial, and how does it…
Elizabeth Brem , MD discusses the design and outcomes of the study referred to as 1826. The study aimed to enhance outcomes and address toxicities in Hodgkin lymphoma treatment. Nivolumab’s potential benefits in comparison to brentuximab within the AVD backbone were explored. Additionally, Brem highlights the collaborative nature of the study, involving adult and pediatric cooperative groups, Canadian cooperative groups, and the children’s oncology group. This collaboration played a pivotal role in the trial’s success, enabling rapid accrual and earlier achievement of primary endpoints.Elizabeth Brem emphasizes that the study achieved its primary objective by improving progression-free survival in patients with…
Shirin Attarian, MD addresses the escalating incidence of head and neck cancer and highlights that most cases, particularly oropharyngeal cancers, are driven by HPV virus infection. She discusses HPV vaccination recommendations, suggesting that individuals between 11 and 26 years old should be vaccinated, potentially starting from age 9. Vaccination for those aged 27-45 is possible after physician consultation but might be less effective due to prior exposure. Beyond 45, there are no current vaccination recommendations. Attarian explains that despite younger generations getting vaccinated, the incidence of head and neck cancer is anticipated to rise in older individuals who aren’t vaccinated.…
Nataliya Mar, MD Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, provides GU ASCO Updates [2023]. What were the VESPER trial results? What were the CONTACT-03 trial results? In the case of the 68-year-old man with metastatic prostate cancer, who had initial response but then developed PSA rise, what are the key considerations when selecting treatment options for patients with somatic and germline DDR alterations? How do PARP inhibitors fit into the treatment landscape? What were the TALAPRO-2 trial results?
Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, leading and overseeing the company’s global oncology research and development activities. In a pivotal Phase 3 randomized clinical trial, niraparib maintenance therapy has demonstrated remarkable efficacy for patients recently diagnosed with advanced ovarian cancer following initial platinum-based chemotherapy. This trial, involving 384 participants, unveiled the significant potential of niraparib in extending progression-free survival rates by a substantial 55% when compared to a placebo control group. Notably, the treatment’s effectiveness was observed across diverse patient subsets, regardless of their biomarker status or the presence of residual disease. These findings…
Pre-Roll Example
Advertising on OncologyTube For A Limited Time No Contracts! Pay As You Go! Book Now! or Contact Us for More Info or Call 1 (951) 944-2173 (Discounts available for 3, 6, and 12 month contracts) Why OncologyTube? $120 CPM the lowest in the industry (for a limited time only) 90% of our unique content is created by MD oncologists for oncologist. We work with the biggest pharmaceutical, research hospitals, and universities in the world. The most well-known oncology KOLs and researchers contribute to our platform. 10,000+ NPI-verified oncologists subscribed to our monthly eNewsletter. Thousands more worldwide. 20,500+ Social Media followers mostly…
Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX The talk covered the emerging field of menin inhibition in AML, shedding light on its potential as a novel therapeutic strategy. The enthusiasm around this development was palpable in the presentation, reflecting the speaker’s excitement for the advancements in understanding and treating AML. Additionally, the evolving classification of AML was discussed, showcasing the dynamic nature of the field and the constant discovery of new entities within it. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US…
Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) In a captivating interview, Yasmin Abaza, MD, an esteemed Assistant Professor of Medicine at Northwestern University, delved into her research focus on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Offering a comprehensive overview of immune cell therapies for these conditions, Dr. Abaza touched upon the historical struggles encountered in achieving successful outcomes. She candidly highlighted the limited success observed thus far while shedding light on the promising agents currently undergoing clinical trials. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…
Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Jessica Altman, MD, a dedicated professional at Northwestern University in Chicago, recently participated in her first conference, which proved to be a remarkable experience. At this event, she engaged in a thought-provoking debate with Dr. Dauver, focusing on the treatment of acute myeloid leukemia (AML) in adults with newly diagnosed cases. The debate centered on the comparison between triplet-based therapy and sequential therapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…
Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD a dedicated professional at MD Anderson in Houston, Texas, recently presented groundbreaking insights at a conference. Formerly dire disease survival rates have been revolutionized, with ten-year survival now at an impressive ninety percent within four to five years. This transformation represents a new standard of care and a remarkable advancement for patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…
The discussion focuses on the changing landscape of treatment for mutated acute myeloid leukemia (AML). The speaker emphasizes the significance of mutation profiles in AML patients, which can have prognostic or therapeutic implications. Poultry inhibitors are believed to have a lasting impact, with many candidates already approved or under investigation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The session’s agenda involves a brief introduction followed by experts discussing various aspects of…
Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Bijal Shah MD, MS,…
Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, delves into the genomic classification of Acute Lymphoblastic Leukemia (ALL) and its diagnostic approaches. He covers three main areas: B-cell ALL (BOL), implications for risk stratification and diagnosis, and insights into the classification of T-cell ALL (TOL). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com After a decade of genomic research,…
Sayeh Lavasani, MD of UCI Health gives an Update in Breast Cancer at MOASC’s Spotlight on Oncology NATALEE’s study focused on comparing adjuvant ribocyclib plus a non-steroidal AI versus an AI alone in high-risk, early-stage, hormone receptor-positive breast cancer patients. The ribocyclib was administered at a lower dose of 400 milligrams daily for three weeks on and one week off, over three years. This study showed improvements in invasive disease-free survival, as well as trends towards enhanced overall survival in a three-year follow-up. These findings suggest an additional treatment option to reduce the risk of recurrence in earlier-stage hormone-positive breast…
Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD expresses gratitude for the audience’s presence and thanks the event organizers for the invitation. They introduce themselves as a pediatric oncologist speaking at an adult conference, focusing on pediatric AAA (acute lymphoblastic leukemia) and 4-1BB CAR T cell therapies. They mention the high complete response (CR) rates of up to 97% achieved with CAR19 (CAR targeting CD19), but also note the significant challenge of disease relapse after CAR19 treatment, especially in pediatric and adult patients. They attribute relapse to two main…
Shira N. Dinner, MD- Robert H Lurie Cancer Center Shira N. Dinner, MD discussed several studies focused on the treatment of acute lymphoblastic leukemia (ALL) in older adults, particularly those aged 55 and above. The presentation highlighted the challenges and outcomes associated with different treatment approaches. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTSAML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Shira N. Dinner, MDfirst emphasized the historical poor outcomes for older adults with ALL, with survival rates being notably lower compared to…
Hagop Kantarjian, MD is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center Hagop Kantarjian, MD shared exciting updates and progress in the treatment landscape. Notably, some of the predictions made back in 2010 are now proving to be successful. Initiatives like the development of the blinatumomab and inotuzumab therapies started in 2008 and by 2010, it was clear that using them as standalone treatments would not be effective, prompting a shift towards combination therapies. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTSAML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/AML-ALL EU -…
When your patient is diagnosed with a blood cancer such as chronic lymphocytic leukemia (CLL), it’s important to remember that in addition to their physical health, their mental health is a critical part of their overall well-being.1 From initial diagnosis through remission, it’s essential to ensure patients are equipped with tools and resources to help them manage the various emotions that come with a diagnosis and know how to seek professional help when needed. Many patients feel a certain stigma around mental health, so it’s important to initiate the conversation. Helping patients figure out how to create an action plan…
Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Nitin Jain, MD, discussed relapsed/refractory T-cell acute lymphoblastic leukemia (TLL) and the need for new therapies due to the ineffectiveness of current treatments. They highlighted studies that assessed outcomes in relapsed TLL, demonstrating a median survival of four to six months, indicating the significant unmet medical need. Nitin Jain, MD, also mentioned the criteria for defining early T-cell precursor leukemia (ETPL) based on gene expression and flow cytometry markers. They discussed different approaches for treating…
Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Bijal Shah MD, MS,…
Marina Konopleva, MD, PhD – University of Texas MD Anderson Cancer Center and Albert Einstein College of Medicine Jack and Pearl Resnick Campus The discussion revolved around patients with B-cell acute lymphoblastic leukemia (ALL) that had a gene expression signature similar to Philadelphia chromosome-positive ALL (Ph+ ALL) but lacked the characteristic genetic abnormalities. This subgroup, referred to as “PH-like ALL,” comprised around 20-30% of ALL cases, with a higher prevalence in pediatric patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ ML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…
Marlise Luskin,MD, MSCE- Medical Oncology- Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the adult leukemia program. The presentation focused on the use of the drug venetoclax (and its related drugs) in the treatment of acute lymphoblastic leukemia (ALL), particularly relapse refractory ALL. The speaker outlined the significant progress that has been made in the treatment of this disease, including various therapies like blinatumomab, iituzumab, and CAR T cell therapy, which have shown improvements but still leave certain subsets of patients with unmet needs. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content…
Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD discussed the potential treatment options for patients facing relapsed leukemia during a medical presentation. He emphasized the importance of considering complementary strategies rather than competing ones. Dr. Jabbour advocated starting with bispecific and immunotherapy approaches before utilizing CAR T-cell therapy due to their positive impact on survival. He referred to the dire prognosis of relapsed patients, comparing it to a death sentence, and highlighted the challenges associated with traditional treatments like transplantation. REGISTER NOW TO JOIN US AT THESE UPCOMING…